Stay updated on Avatrombopag Safety & Efficacy in ITP Clinical Trial
Sign up to get notified when there's something new on the Avatrombopag Safety & Efficacy in ITP Clinical Trial page.

Latest updates to the Avatrombopag Safety & Efficacy in ITP Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe history now includes a new revision v3.4.2 and the previous v3.4.1 entry has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check19 days agoChange DetectedThe history now lists a new revision entry v3.4.1 and the previous revision v3.4.0 was removed. This is a backend versioning update rather than a change to the study record content.SummaryDifference0.1%

- Check41 days agoChange DetectedAdded a new revision entry v3.3.4 to the Record History, following the previous version v3.3.3. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check62 days agoChange DetectedRevision: v3.3.3 was added to the record history. The HHS Vulnerability Disclosure link and Revision: v3.3.2 were removed.SummaryDifference0.2%

- Check91 days agoChange DetectedThe study record history shows a new revision entry v3.3.2 and removal of v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check99 days agoChange DetectedThe header notice about a lapse in government funding was removed and replaced with the standard government disclaimer that the U.S. government does not review or approve the safety and science of listed studies. This change affects site messaging but not the trial record content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

Stay in the know with updates to Avatrombopag Safety & Efficacy in ITP Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Avatrombopag Safety & Efficacy in ITP Clinical Trial page.